麗珠醫藥(01513.HK)注射用艾普拉唑鈉繼續納入醫保目錄
格隆匯12月3日丨麗珠醫藥(01513.HK)公吿,2021年12月3日,國家醫療保障局及人力資源社會保障部發布了《國家醫保局人力資源社會保障部關於印發〈國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)〉的通知》,公司重點產品注射用艾普拉唑鈉通過談判續約,繼續納入新版《醫保目錄》。
注射用艾普拉唑鈉於2018年1月獲批生產,於2019年11月通過談判首次納入2019年版《醫保目錄》。注射用艾普拉唑鈉本次參加國家醫保續約談判,一系列新的臨牀證據證明本產品具有更顯着的療效、安全性和經濟性,經多輪溝通,最終簽約成功,且本次續談結果取消了原報銷範圍中“禁食醫囑或吞嚥困難”的限制,使得適用性更廣,方便臨牀處方且患者獲益更多。公司未來將持續加強本產品的市場拓展,不斷提高醫院覆蓋及產品銷量,減少醫保支付價格調整對公司業績穩健增長帶來的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.